BioMedReports | TalkMarkets | Page 3
Biotech Investing, Healthcare Stocks
Contributor's Links: BioMedReports
BioMedReports.com was co-founded by M.E. Garza and Mike Havrilla in early 2009. Both were successful traders and investors who had historically made some of their more

Articles

Latest Posts
33 to 48 of 49 Posts
Healthcare Review: GILD, AZN, ASTM, EXAS, LAKE
Ebola-related issues continue to head north. Alpha Pro Tech is up 29% on strong volume.
RMTI Announces FDA Committee Review Of Triferic; HZNP Presents Results Of ACTIMMUNE(R)
Rockwell Medical, Inc. a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services. Horizon Pharma plc announced the presentation of data from a Phase 2 clinical study of ACTIMMUNE
AMGN Declares A Head-to-Head Phase III; CNAT Reports Acceptance Of Abstract For AASLD Meeting
Amgen (AMGN) has claimed gaining regulatory approval for its biosimilar of Humira, AbbVie's (ABBV) mega blockbuster anti-inflammatory drug.
RNN New Nanotechnology Patent Creates Next-Generation Docetaxel, Gemcitabine, And Cisplatin
Targeted cancer therapy is a revolution in drug company research, and Rexahn Pharmaceuticals, Inc. recent recipient of a notice of allowance from the US Patent and Trademark Office for a new delivery platform, might one day join the leagueof bigger players.
Healthcare Review: OBCI, RGBP, ARWR, UNIS, SLXP
U.S. stocks extended gains as investors speculated the Federal Reserve would keep interest rates lower for longer on concern that a global slowdown will hurt the American economy.
BMY Withdraws NDA On Asunaprevir In The US; BCRX Reports On OPuS-1 Phase 2 Trial Results
Bristol-Myers Squibb has decided that it will not pursue FDA approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States.BioCryst Pharmaceuticals, Inc. announced results from its successful OPuS-1 (Oral ProphylaxiS-1).
Healthcare Review: ISR, CBMX, THC, PSTI
U.S. stock indexes are following other global markets lower in early trading. European stocks fell after Germany reported the biggest monthly drop in industrial production in five years.
Biotech Investors Gamble On Ebola Stocks
The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA’s awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more than constant media attention.
Healthcare Review: PTCT, HLF ALQA, ARIA, ADHD
Global equity markets extended a rally on Monday that drew strength from a forecast-beating U.S. jobs report last week that bolstered confidence in the American economy and the Federal Reserve's monetary policy, but the dollar gave up some of its gains.
Healthcare Review: FHCO, GOVX, HTBX, ARIA, INCY
US stocks fluctuated amid an unexpected decline in jobless claims, while European equities plunged and the euro rose on concern additional stimulus will fail to boost inflation and revive the economy.
Healthcare Review: CPRX, CANF, ACST, NWBO, ACT
The Dow Jones Industrial Average rose 37 points, or 0.2%, to 17108. The S&P 500 added four points, or 0.2%, to 1982, and the Nasdaq Composite Index rose six points, or 0.1%, to 4512.
Medidata Appoints Mike Capone COO; PV-10 Data At Esmo 2014 Show
Medidata the leading global provider of cloud-based solutions for clinical research in life sciences, announced Michael L. Capone is joining the company as chief operating officer COO.
Healthcare Review: CLVS, CBAY, PVCT, TNXP, SGEN
Global equity markets fell on Monday as civil unrest in Hong Kong weighed on investor sentiment, while U.S. Treasury debt prices rose over uncertainty sparked by the protests.
CRMD Announces FDA IND Filing For Neutrolin; ZFGN Completes Enrollment Of Phase 2a Trial Of Beloranib
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease.
Healthcare Review: IG, ABBV, ECTE, RNN, OFIX
The S&P 500 fell 29 points, or 1.5%, to 1969. The Nasdaq NDAQ -1.61% Composite Index declined 83 points, or 1.8%, to 4472.
Healthcare Review: ELMD, EGLT, ECTE, ATOS, CBMX
The Dow Jones Industrial Average gained 102 points, or 0.6%, to 17158. The S&P 500 index added 10 points, or 0.5%, to 1993 and the Nasdaq Composite rose 34 points, or 0.8%, to 4543.
33 to 48 of 49 Posts